openPR Logo
Press release

Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy

07-09-2020 10:59 AM CET | Health & Medicine

Press release from: Anergis SA

/ PR Agency: akampion
- Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant -

Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of TRANSVAC2, the European Network of Vaccine Research and Development funded under the European Union's Horizon 2020 Research and Innovation Program.

The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat house dust mite allergy (the Der p 2 COPs) when presented on Virometix’ proprietary Synthetic Virus-Like Particles (SVLP), with or without undisclosed Toll-Like Receptor (TLR) ligands and built-in adjuvants, and will compare the results to Anergis’ Der p 2 COPs with aluminum hydroxide as an extrinsic adjuvant. More broadly, this study will provide information on the applicability of the two technology platforms combined for combatting allergies.

The study was launched at HZI in Q2/2020 and the results are expected by Q4/2020.

“Given the immune-stimulatory properties of the SVLP platform and the extensive clinical experience with Anergis’ COPs, we are convinced that the combination of SVLPs with dust mite COPs represents a highly attractive opportunity to develop a safe and efficacious ultra-fast COP allergy vaccine platform,” commented Alexander Kettner, Head of Research at Anergis.

“We are very excited to start this initial research project with Anergis, a leading company in ultra-fast allergy immunotherapy,” said Anna Sumeray, CEO of Virometix. “We look forward to demonstrating that our proprietary Synthetic Virus-Like Particle (SVLP) technology and vaccine expertise can improve the treatment of allergies.”


TRANSVAC2 functions as a leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe, and contributes to the development of effective products to address European and global health challenges. This reinforces the European leadership in controlling the burden and spread of diseases, and the economic assets represented by vaccine developers in Europe.

About Allergies
Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “allergy immunotherapy” is the process of inducing tolerance to the allergen. It typically requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (


Anergis SA
Vincent Charlon; Chief Executive Officer
Biopôle Building SC-A
Route de la Corniche 4
CH-1066 Epalinges

Virometix AG
Anna Sumeray, Chief Executive Officer,

Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

About Anergis
Anergis SA is a privately held Swiss biopharmaceutical company dedicated to the discovery and development of proprietary ultra-fast allergy immunotherapy products for the most prevalent allergies. Anergis was founded by Professor François Spertini, allergist at the University Hospital of Lausanne, Switzerland. Anergis raised over CHF 55 million from private and institutional investors, including BioMedInvest, Sunstone Capital, Renaissance PME and WJFS, Inc. Anergis SA is located in the Biopôle near Lausanne, Switzerland, a life sciences community bringing together industry and academia.

About Virometix
Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.

About Helmholtz Centre for Infection Research
Scientists at the Helmholtz Centre for Infection Research (HZI) investigate the mechanisms of infectious diseases and the defence against them. Subsequently, they develop the results of basic research systematically towards medical and pharmaceutical application. The HZI addresses the infectious disease challenges of the 21st century. To this end, the centre has implemented its competitive programme “Infection Research”. The programme puts particular emphasis on the transfer of research results to application as anti-infectives, vaccines and diagnostics. There is a strong focus on individualised infection medicine and the increased use of big data-driven approaches for infection research, including omics-technologies and machine learning tools.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy here

News-ID: 2087314 • Views:

More Releases from Anergis SA

Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generat …
- The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability - Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible EPALINGES, Switzerland, December 13th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study

More Releases for Virometix

Vaccine Adjuvants Market 2021-2026 | Industry Overview, Growth, Trends and Forec …
According to the latest report by IMARC Group, titled, "Vaccine Adjuvants Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2021-2026", the global vaccine adjuvants market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 12% during 2021-2026. Vaccine adjuvants refer to compounds that enhance the immunogenic reaction of the body against antigens that have insufficient immunostimulatory capabilities. An adjuvant
Cervical Cancer Market Significantly Stepping towards the Success Till 2027
Cervical cancer is a cancer of the cervical cells. The most typical symptom of this type of cancer is vaginal bleeding; but, in some cases, no symptoms appear until the cancer has progressed to an advanced stage. More than 90% of cervical cancers are caused by HPV (Human papillomavirus) infection and are detected through smear screening. Request Sample Copy of this Report: Top Key Players Included in This Report: Virometix, Merck,
Global Cancer Diagnostic Testing Analyzers Market Research Report by key players …
The global Cancer Diagnostic Testing Analyzers Market is valued at million US$ in 2019 is expected to reach peak by the end of 2025, growing at a huge CAGR during 2019-2025. Ask for Exclusive Sample Report at – This report focuses on Cancer Diagnostic Testing Analyzers Market volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cancer Diagnostic Testing Analyzers
Cervical Cancer Diagnostic Testing Market by Top Key Players - GlaxoSmithKline, … present the report on global Cervical Cancer Diagnostic Testing Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2023. This report focuses on the Cervical Cancer Diagnostic Testing market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the
Global Cervical Cancer market Research Report Scope, Deep Analysis, Industry Siz …
Global Cervical Cancer market Research Report Scope, Deep Analysis, Industry Size, Market Analysis, Competitive Market and Forecast 2023 Cervical cancer is generally characterized by the abnormal growth of the cancerous cells in the tissues of the cervix and may manifest itself as a squamous-cell carcinoma or adenocarcinoma. The report titled as global cervical cancer market gives a brief about the comprehensive research and an outline of its growth in the market
Cervical Cancer Global Market by Application, Analysis and Outlook to 2019
Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms